Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth M de Tute

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bone Marrow Transplantation|January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialRuth M de Tute, Gordon Cook, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
The Lancet. Haematology|December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, William Wilson, Ruth M de Tute, et al.
Blood|August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic ProfilingSina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bone Marrow Transplantation|January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialRuth M de Tute, Gordon Cook, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
The Lancet. Haematology|December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trialKwee Yong, William Wilson, Ruth M de Tute, et al.
Blood|August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic ProfilingSina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Pageof 2